沙库巴曲缬沙坦联合重组冻干人脑利钠肽治疗慢性心力衰竭患者的效果
Effects of Sacubitril/Valsartan combined with lyophilized recombinant human brain natriuretic peptide in treatment of patients with chronic heart failure
刘丹阳1
作者信息
- 1. 西华县人民医院心内二科,河南 周口 466000
- 折叠
摘要
目的:观察沙库巴曲缬沙坦联合重组冻干人脑利钠肽(rhBNP)治疗慢性心力衰竭(CHF)患者的效果.方法:选取2021 年 6 月至 2023 年 6 月该院收治的 98 例CHF患者进行前瞻性研究,按随机数字表法将其分为观察组与对照组各 49 例.对照组给予注射用rhBNP治疗,观察组在对照组基础上联合沙库巴曲缬沙坦钠片治疗,比较两组临床疗效,治疗前后心功能指标[左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)]水平、血液流变学指标水平,以及不良反应发生率.结果:观察组治疗总有效率为 95.92%(47/49),高于对照组的 83.67%(41/49),差异有统计学意义(P<0.05);治疗后,两组LVEF水平均高于治疗前,且观察组高于对照组,两组LVEDD、LVESD水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组全血高切黏度、全血低切黏度、血浆黏度水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05).结论:沙库巴曲缬沙坦联合rhBNP治疗CHF患者可提高治疗总有效率,改善心功能指标水平,降低血液流变学指标水平,其效果优于单纯rhBNP治疗.
Abstract
Objective:To observe effects of Sacubitril/Valsartan combined with lyophilized recombinant human brain natriuretic peptide(rhBNP)in treatment of patients with chronic heart failure(CHF).Methods:A prospective study was conducted on 98 patients with CHF admitted to this hospital from June 2021 to June 2023.According to the random number table method,they were divided into observation group and control group,49 cases in each group.The control group was treated with rhBNP for injection,while the observation group was treated with Sacubitril/Valsartan sodium tablets on the basis of that of the control group.The clinical efficacy,the levels of cardiac function indexes[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD)],the hemorheology index levels before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 95.92%(47/49),which was higher than 83.67%(41/49)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the LVEF levels of the two groups were higher than those before the treatment,and that in the observation was higher than that in the control group;the levels of LVEDD and LVESD in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;and the differences were statistically significant(P<0.05).After the treatment,the levels of whole blood high shear viscosity,whole blood low shear viscosity and plasma viscosity in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Sacubitril/Valsartan combined with rhBNP in the treatment of the CHF patients can improve the total effective rate of treatment,improve the levels of cardiac function indexes,and reduce the levels of hemorheology indexes.Moreover,it is superior to single rhBNP treatment.
关键词
慢性心力衰竭/重组冻干人脑利钠肽/沙库巴曲缬沙坦/心功能/血液流变学/不良反应Key words
Chronic heart failure/Lyophilized recombinant human brain natriuretic peptide/Sacubitril/Valsartan/Cardiac function/Hemorheology/Adverse reaction引用本文复制引用
出版年
2024
NETL
NSTL
维普
万方数据